

GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

Company

2023/09/21 22:00:00



Price
75.27
USD

Difference  **-0.73% (-0.55)**



Contact Details

GILEAD SCIENCES INC. Tel: +1-650-574-3000
 -- Fax: +1-650-522-5853
 333 Lakeside Drive Web: <http://www.gilead.com>
 94404 Foster City E-mail: -

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	14,443,000,000		14,772,000,000		15,996,000,000	
Common stock capital		1,000,000		1,000,000		1,000,000
Fixed assets	48,728,000,000		53,180,000,000		52,411,000,000	
Equity capital of a company		21,209,000,000		21,064,000,000		18,221,000,000
Cash and cash equivalents	5,412,000,000		5,338,000,000		5,997,000,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		11,237,000,000		11,610,000,000		11,397,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		30,725,000,000		35,278,000,000		38,789,000,000
Different income		-		-		-
Other liabilities		5,095,000,000		5,254,000,000		9,536,000,000
Total assets	63,171,000,000	63,171,000,000	67,952,000,000	67,952,000,000	68,407,000,000	68,407,000,000

Balance notes

	2022	2021	2020
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	17,000	14,400	13,600
Equity ratio	33.52%	30.99%	26.66%
Debt-equity ratio	198.29%	222.67%	275.04%

Others

	2022	2021	2020
Tax Expense Rate	21.47%	25.09%	94.67%

GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

Income statement

	2022	2021	2020
Turnover	27,085,000,000	27,372,000,000	24,642,000,000
Net income	4,592,000,000	6,225,000,000	123,000,000
EBIT	6,312,339,700	8,678,648,700	2,481,350,900
Operating income before taxes	5,814,000,000	8,278,000,000	1,669,000,000
Cash Flow	9,072,000,000	11,384,000,000	8,168,000,000
Net interest income	-935,000,000	-1,001,000,000	-984,000,000
Research and development expenses	4,998,000,000	5,363,000,000	4,857,000,000
Income taxes	1,248,000,000	2,077,000,000	1,580,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,490,153	1,777,849	1,694,681

Board of Directors

Members of Management Board

Jacqueline Barton	Member of Board of Directors
Jeffrey Bluestone	Member of Board of Directors
Sandra Horning	Member of Board of Directors
Anthony Welters	Member of Board of Directors
Harish M. Manwani	Member of Board of Directors
Javier Rodriguez	Member of Board of Directors
Kelly Kramer	Member of Board of Directors
Kevin Lofton	Member of Board of Directors
Daniel O'Day	Chairman of Managing Board
Adam Levy	Member of Executive Committee
Flavius Martin	Member of Executive Committee
Linda Higgins	Member of Executive Committee
Mark Chao	Member of Executive Committee
Mark Genovese	Member of Executive Committee
Merdad Parsey	Member of Executive Committee
Sarah Miksinski	Member of Executive Committee
Stacey Ma	Member of Executive Committee
Tomas Cihlar	Member of Executive Committee
William Grossman	Member of Executive Committee
Andrew Dickinson	Member of Executive Committee
Cindy Perettie	Member of Executive Committee
Deborah Telman	Member of Executive Committee
Dustin Haines	Member of Executive Committee
Jacquie Ross	Member of Executive Committee
Janet Dorling	Member of Executive Committee